Herpesviridae infectious disease
MONDO:0005794Virus diseases caused by the herpesviridae.
Also known as: Herpesviridae caused disease or disorder, Herpesviridae disease or disorder, Herpesviridae infections, herpesvirus infection, Herpesviridae infection, Herpesvirus infection, Herpesvirus infections, herpes infection
294 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a new vaccine beat chickenpox? large trial underway
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …
Phase: PHASE3 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New chickenpox vaccine trial aims to protect 300 kids
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine in 300 healthy children aged 1 to 12 years. All children will receive one dose of the vaccine. Researchers will check if the vaccine triggers a strong immune response and is safe to use.
Phase: PHASE3 • Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
-
New mRNA vaccine targets Epstein-Barr virus in first human trial
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is li…
Phase: PHASE1 • Sponsor: Vaccine Company, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:25 UTC
-
New mRNA shingles vaccine enters phase 2 trial – could it be a game changer?
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new mRNA vaccine called SYS6017 to prevent shingles, a painful rash caused by the chickenpox virus. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how well the v…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
MRNA vaccine aims to prevent shingles in older adults
⭐️ VACCINE ⭐️ Not yet recruitingThis phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:54 UTC
-
New trial aims to stop CMV eye inflammation from returning
Disease control Not yet recruitingThis study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. T…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
A pharmacist in the dentist's chair: could a new team approach tame stubborn mouth conditions?
Disease control Not yet recruitingThis trial tests whether adding a clinical pharmacist to dental care can improve how oral mucosal disorders — such as oral lichen planus, recurrent canker sores, burning mouth syndrome, oral thrush, and herpes infections — are managed. Dentists in some clinics will get pharmacist…
Phase: NA • Sponsor: University of Fujairah • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a vaccine protect your heart? study tests shingles and RSV shots against artery plaque
Disease control Not yet recruitingThis study investigates whether two common vaccines—the shingles vaccine (RZV) and an RSV vaccine (RSVPreF3)—can slow the buildup of fatty plaque in the coronary arteries. The trial enrolls adults aged 50 and older who are at risk for cardiovascular events. Participants receive e…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a cancer drug wake up immune cells to beat HIV-Related infections?
Disease control Not yet recruitingThis study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Transplant drug tweak may tame common virus
Disease control Not yet recruitingThis study tests whether adjusting the dose of anti-rejection drugs can help control CMV infection in organ transplant recipients. About 100 adults who have had a kidney, liver, heart, lung, or pancreas transplant and now have a CMV infection will take part. Researchers will moni…
Phase: PHASE4 • Sponsor: Oriol Manuel • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Washing kidneys to stop hidden virus: new trial aims to make transplants safer
Disease control Not yet recruitingThis early-stage trial tests whether treating a donor kidney with a drug called SYN002 before transplant can safely reduce the risk of passing cytomegalovirus (CMV) to the recipient. About 12 adults waiting for a kidney transplant will receive a treated organ. The main goal is to…
Phase: EARLY_PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could 4 months of antiviral drugs be enough for CMV-Infected newborns?
Disease control Not yet recruitingThis study compares a 4-month course of antiviral medication (ganciclovir or valganciclovir) against the standard 6-month course for babies born with moderate-to-severe congenital CMV infection. The goal is to see if the shorter treatment works just as well at preventing long-ter…
Phase: PHASE4 • Sponsor: Hu Bofei • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New scoring system could cut Post-Transplant infections
Disease control Not yet recruitingThis study tests a scoring system that uses immune system recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from causing infection. About 1,114 transplant recipients will take part to…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a common antiviral save lives in advanced HIV?
Disease control Not yet recruitingThis study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will be randomly assigned to take either valganciclovir or a place…
Phase: PHASE2 • Sponsor: Wits Health Consortium (Pty) Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody shows promise against Post-Transplant virus threat
Disease control Not yet recruitingThis phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immune cell boost may help kids beat Post-Transplant viruses
Disease control Not yet recruitingThis study tests whether adding immune cells from a family donor to standard antiviral drugs can help children and young adults clear stubborn adenovirus or cytomegalovirus infections after a stem cell transplant. About 69 participants will be randomly assigned to receive either …
Phase: PHASE3 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New study aims to stop CMV in kidney transplants
Disease control Not yet recruitingThis study tests two different drug combinations to prevent cytomegalovirus (CMV) infection in kidney transplant patients who are at high risk. Thirty adults who are CMV-positive before transplant will receive either tacrolimus plus mTOR inhibitors with early antiviral treatment,…
Phase: PHASE4 • Sponsor: Hospital Universitario La Paz • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can a common antiviral tame herpes meningitis?
Disease control Not yet recruitingThis study tests whether the antiviral drug aciclovir (or its pill form valacyclovir) works better than a placebo for treating meningitis caused by the herpes simplex virus type 2 (HSV-2). About 150 adults with confirmed HSV-2 meningitis will receive either the drug or a placebo,…
Phase: PHASE4 • Sponsor: Jacob Bodilsen • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New miRNA test could spot hidden virus after transplant
Diagnosis Not yet recruitingThis study will test a new blood test that looks for tiny molecules called miRNAs to detect HCMV infection earlier in people who have received a stem cell transplant. The standard DNA test can miss early signs, so researchers hope this new method will give doctors a head start. A…
Sponsor: Ting YANG • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Could a cheaper shingles booster offer same protection?
Prevention Not yet recruitingThis trial tests whether a single dose of a live-attenuated shingles vaccine can effectively boost immunity in adults aged 50 and older who have already received the recombinant shingles vaccine. The study measures antibody and cellular immune responses after the booster. If it w…
Phase: EARLY_PHASE1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Can a new Four-in-One vaccine match the gold standard for childhood protection?
Prevention Not yet recruitingThis study tests an investigational vaccine that combines protection against measles, mumps, rubella, and chickenpox (varicella) in a single shot. It will be given as a second dose to healthy children aged 4 to 6 years who have already received a first dose of a similar vaccine. …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Could a daily pill shield transplant patients from a common virus?
Prevention Not yet recruitingThis study investigates whether the drug letermovir can prevent cytomegalovirus (CMV) infection in adults who have received a kidney or liver transplant and have been previously exposed to CMV. Participants take one letermovir tablet daily for 84 days after transplant. The goal i…
Phase: PHASE4 • Sponsor: University of Wisconsin, Madison • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
Could a cancer drug stop a deadly complication in transplant patients?
Prevention Not yet recruitingThis study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…
Phase: PHASE1 • Sponsor: Jennifer Amengual • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
New drug may offer safer CMV prevention for kidney transplant patients
Prevention Not yet recruitingThis study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…
Phase: PHASE4 • Sponsor: Elisabeth Kincaide • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Could a common steroid prevent a deadly complication in AIDS patients?
Prevention Not yet recruitingThis study tests whether a short course of the steroid prednisolone can prevent paradoxical immune reconstitution inflammatory syndrome (IRIS) in people with AIDS who have low CD4 counts and are starting HIV treatment. About 131 participants will receive either prednisolone or no…
Phase: NA • Sponsor: Shanghai Public Health Clinical Center • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New shingles shot shows promise in Mid-Stage trial
Prevention Not yet recruitingThis study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox viru…
Phase: PHASE2 • Sponsor: CHA Vaccine Institute Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Donor t cells aim to block virus after transplant
Prevention Not yet recruitingThis early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. …
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Could a booster shot shield transplant patients from shingles?
Prevention Not yet recruitingThis study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-supp…
Phase: PHASE2 • Sponsor: Oriol Manuel • Aim: Prevention
Last updated Jun 27, 2026 09:09 UTC
-
New drug aims to stop EBV in kidney transplants
Prevention Not yet recruitingThis study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, along…
Phase: PHASE2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Jun 27, 2026 08:14 UTC
-
Shingles vaccine tested for lung cancer patients: could it boost survival?
Prevention Not yet recruitingThis study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Prevention
Last updated Jun 26, 2026 16:12 UTC
-
New gel promises shingles pain relief in minutes
Symptom relief Not yet recruitingThis study tests a special gel applied to the skin to see if it can quickly reduce pain from shingles. Thirty adults with shingles-related pain will receive a single application of the gel. Researchers will measure pain levels before and after application, focusing on relief with…
Phase: NA • Sponsor: Nakhia Impex LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Could a steroid injection stop shingles pain for good?
Symptom relief Not yet recruitingThis study tests whether dexamethasone palmitate, a steroid, can better relieve shingles pain and prevent long-term nerve pain compared to standard care. About 954 adults with shingles rash and severe pain will receive the drug by injection or infusion. Researchers will track pai…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New study eyes monthly virus tests to shield transplant kidneys
Knowledge-focused Not yet recruitingThis study will follow 1000 kidney transplant patients for one year to see if monthly blood tests for certain viruses (CMV, BK, and TTV) can help predict and prevent serious infections and kidney damage. The goal is to learn how the body's immune system and virus levels relate to…
Sponsor: Transplant Genomics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New blood tests could sharpen CMV monitoring in transplant patients
Knowledge-focused Not yet recruitingThis study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplan…
Sponsor: University of Rome Tor Vergata • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Blood test after transplant may flag hidden virus risk
Knowledge-focused Not yet recruitingThis study follows 123 stem cell transplant patients to see if measuring their immune response to CMV after stopping a preventive drug (letermovir) can predict late infections. Participants will have regular blood tests up to 200 days after transplant. The goal is to learn whethe…
Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
CMV's hidden impact on transplant immunity under the microscope
Knowledge-focused Not yet recruitingThis study looks at how CMV (a common virus) changes the immune system in people who have had a kidney transplant. Researchers will take blood samples from 60 patients to compare immune responses in those with and without CMV infection. The goal is to understand why CMV may incre…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:58 UTC